September 28, 2015 Off

Cyramza Phase II study meets its primary endpoint

By Dino Mustafić

Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.